Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: USA-Based Family Office Invests in Early-Stage Companies Across the Globe, With Strong Interest in Therapeutics Opportunities

8 Apr

A family office based in the USA has several decades of experience in investing in life science companies and taking them public. The firm participates in deals across all stages of development, from seed to mezzanine funding. In early-stage deals, the firm’s initial check size is usually between $250-500K, with potential for follow-on financing as the companies achieve key growth milestones. The firm is actively involved with a well-established angel investor group and makes investments through this group as well. The firm is open to opportunities all across the globe.

The firm seeks to invest broadly across different silos of the life sciences ecosystem, from therapeutics, devices, diagnostics, and digital health. The firm’s strongest interest and expertise lies in biotech, and many of the firm’s investments have been in therapeutics companies. The firm is also open to companies of all stages of development and is indication agnostic, but has significantly higher standards for oversaturated, competitive spaces such as oncology.

The firm has no explicitly stated company or management team requirements. The firm likes to become actively involved in their portfolio companies and supports them with needed resources and advisory services to help them grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Asia Cross Border VC Firm Invests in Therapeutics, Devices, and Diagnostics, Open to USA & China-Based Companies

8 Apr

A venture capital firm headquartered in Taiwan currently manages a fund focuses 50% on bio & healthcare-related investments, and outside of life sciences the firm invests in all types of high potential technologies with disruptive potential. The firm primarily seeks investment opportunities in USA, China and Taiwan.

The firm is most interested in novel therapeutics, but also invests in medical devices and diagnostics. Within therapeutics, the firm has invested across various modalities, from traditional small molecule therapeutics to emerging therapies like immunotherapy and cell/gene therapy. The firm is open to pre-IND, early-stage opportunities given they have a valid proof of concept and address an area of unmet medical need. As for medical devices, the firm generally invests in 510k products and open to all types of devices that address unmet medical need.

The firm has no specific company or management team requirements. Though the firm is based in Taiwan, the firm does not require any sort of Taiwan angle or market potential when evaluating cross-border opportunities. The firm is open to leading and co-investing in investment rounds and will most likely seek board representation when acting as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Western Europe VC Firm Invests Up to €20M in Early-Stage & Growth Stage Life Science Companies Over Company Life Cycle

8 Apr

A leading Venture Capital firm investing in early-and growth stage life science companies has multiple offices in Western Europe. The firm is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totaling EUR 1.0 billion, and more than EUR 430 million committed to life sciences, the firm has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, the firm has invested in over 50 innovative life science companies. Initial ticket size ranges between EUR 5-10 million and up to EUR 20 million over the life of the investment.

The firm invests mainly in Europe and selectively in US across five broad areas:  Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology and R&D tools. Regarding therapeutics, the firm focuses on early-stage companies with preclinical proof of concept data or about to enter the clinic, with a preference for companies developing highly innovative technology platforms, or with early clinical data. In the other fields, the firm prefers companies with product candidates (with strong IP protection) approaching regulatory approval or companies who have already launched a first product and have some early market traction in the single million digit range.

The firm typically requests a board seat and looks for a strong and experienced management team while supporting highly talented entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Private Investment Firm Seeks Opportunities in Diagnostics, Digital Health, and Platform Technologies in USA & Canada

8 Apr

A private investment firm is looking to make venture investments in emerging fast growth projects. Typical equity investments range from $500,000 to $3 million per deal. The firm will invest in companies across the United States and Canada.

Currently the firm is most interested in areas of personal medicine diagnostics, particularly in genomics and proteomics. Other areas of high interest include, digital health, platform technologies, nutrition, clean environment, and much more selectively drug development and medical devices. The firm has experience in immunology and is more familiar with vaccine and antibody based technologies. The firm is open in terms of indication and considers orphan indications as well but requires strong data and a clear pathway to exit.

The firm invests in privately held companies and will both lead or co-invest. The firm looks to take a board seat in some of its portfolio companies though it is not a requirement. The firm looks for smart and passionate management teams with high levels of experience in the field.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Mandates: Corporate Venture Fund of Asia-Based Pharma

6 Apr

The corporate venture fund was founded in 2006 and is based in Boston, Massachusetts. The firm is looking to provide equity capital to seed and venture stage companies in the life science space, and invests across North America & Europe. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year.

The fund is currently looking for novel therapeutics, platform technologies, diagnostics, and vaccines. The fund is interested in novel drugs in broad disease areas including neuroscience (particularly neurodegeneration), immunology, inflammation, and rare disease, as well as diagnostics for neurodegenerative disorders. Current platform technology areas of interest include regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine.

The fund strongly prefers that the company has a strong management team with experience in the industry. The firm historically has only invested as a co-investor although they are capable and looking to take a lead position if the correct opportunity arises. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Asia-Headquartered PE Firm Invests in Venture Stage Life Science Companies in Therapeutics, Devices, Diagnostics

1 Apr

A private equity firm headquartered in Asia with multiple offices throughout USA and Asia has a dedicated life science investment team and invests in venture stage companies. The firm invests in various stages, typically start-up and early stage. For life science companies, the firm generally allocates USD 3-5 million per round. The firm is currently focused on opportunities in the US, Israel, and Asia.

The firm invests opportunistically in the life sciences. The firm seeks to invest in innovative therapeutics, diagnostics, and medical devices. For therapeutics, the firm generally invests in novel platform technologies and considers both small molecules and biologics. The firm is indication agnostic and will consider orphan diseases. The firm is also agnostic to the stage of development, but typically invests in companies with a lead asset in clinical trials. For medical devices, the firm is also opportunistic and generally invests in devices that are in the clinic. The firm generally only invests in new IP/NCEs, and does not invest in repurposed or reformulated products.

The firm is currently focused on private companies in the US, Israel and Asia. The firm generally requires a seat on the board of directors or observers.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Investment Arm of Large Holding Company Seeks Diagnostics & Digital Health Technologies Across the Globe

1 Apr

A venture capital fund part of a large holding company looks to provide a unique stepping stone for successful companies to broaden their global reach. The firm offers partners deep understanding of relevant audiences and a unique opportunity for truly innovative, trail-blazing consumer-related digital health ventures. The firm is looking to invest in digital therapeutics, POC diagnostics, and other dHealth companies from seed stage and beyond. The firm is interested in companies with well defined, relevant products and solutions, preferably with initial validation or proof-of-concept. The firm invests globally.

Within the digital health and POC diagnostics space, the firm has many areas of interest. These include, but are not limited to, telemedicine, remote monitoring, patient adherence, femtech and aging, medication dispensing, digital therapeutics, POC and home diagnostics.

The firm has no specific requirements for company and management team, and makes decisions on a case-by-case basis. The firm can lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: